A recent prospective clinical trial in Taiwan has indicated that HLA-B* __number__ screening will reduce the incidence of life-threatening adverse reactions to carbamazepine, while a genome-wide association study has identified the HLA-A* __number__ allele as a genetic risk factor for the full spectrum of carbamazepine-induced cutaneous adverse drug reactions in a European population.